title: Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy.
abstract: OBJECTIVE
  The objective of the study reported here was to evaluate the therapeutic effects of hapten-enhanced chemoimmunotherapy in the treatment of advanced lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy (UMIPIC) and to analyze the effect of this immune booster.
  
  
  METHODS
  A total of 97 patients with advanced lung cancer were treated with UMIPIC or intratumoral chemotherapy (ITCT). UMIPIC was delivered intratumorally in combination with a proprietary therapeutic regimen composed of three components - an oxidant, a cytotoxic drug, and hapten. ITCT applied using the same procedures and regimen, only without hapten. All data from the two groups were reviewed and analyzed. A total of 55 patients were treated with UMIPIC and 42 with ITCT. Patient responses were assessed with computed tomography scan 4-6 weeks after treatment, and all of the patients were followed until their deaths.
  
  
  RESULTS
  Median overall survival was 11.23 months in the UMIPIC (test) group and 5.62 months in the ITCT (control) group (P<0.01). The 6-month and 1-year survival rates of the UMIPIC and ITCT groups were 76.36% versus 45.23% (P<0.01) and 45.45% versus 23.81% (P<0.05), respectively. Two cycles of UMIPIC treatment (n=19) conferred a significant survival benefit compared with two cycles of ITCT (n=29); significant benefits in survival time were also found with UMIPIC (n=20) compared with ITCT (n=13) when both were utilized without adjuvant treatment.
  
  
  CONCLUSIONS
  The hapten-enhanced clinical effect of UMIPIC conferred a superior survival time in patients with advanced lung cancer compared with ITCT. The addition of the hapten in UMIPIC demonstrates a significant advantage in terms of prolonged survival time.
authors.affiliation: Jinan Baofa Cancer Hospital, Jinan; TaiMei Baofa Cancer Hospital, Dongping; Beijing Baofa Cancer Hospital, Beijing, People's Republic of China.
authors.forename: Baofa
authors.initials: B
authors.lastname: Yu
authors.affiliation: Jinan Baofa Cancer Hospital, Jinan.
authors.forename: Yuanfei
authors.initials: Y
authors.lastname: Lu
authors.affiliation: TaiMei Baofa Cancer Hospital, Dongping.
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.affiliation: TaiMei Baofa Cancer Hospital, Dongping.
authors.forename: Peng
authors.initials: P
authors.lastname: Jing
authors.affiliation: Jinan Baofa Cancer Hospital, Jinan.
authors.forename: Han
authors.initials: H
authors.lastname: Wei
authors.affiliation: TaiMei Baofa Cancer Hospital, Dongping.
authors.forename: Peicheng
authors.initials: P
authors.lastname: Zhang
authors.affiliation: Jinan Baofa Cancer Hospital, Jinan.
authors.forename: Guoliang
authors.initials: G
authors.lastname: Liu
authors.affiliation: TaiMei Baofa Cancer Hospital, Dongping.
authors.forename: Ning
authors.initials: N
authors.lastname: Ru
authors.affiliation: TaiMei Baofa Cancer Hospital, Dongping.
authors.forename: Guanghui
authors.initials: G
authors.lastname: Cui
authors.affiliation: Jinan Baofa Cancer Hospital, Jinan.
authors.forename: Xinhai
authors.initials: X
authors.lastname: Xu
authors.affiliation: Jinan Baofa Cancer Hospital, Jinan.
authors.forename: Chenglin
authors.initials: C
authors.lastname: Sun
authors.affiliation: TaiMei Baofa Cancer Hospital, Dongping.
authors.forename: Changjiang
authors.initials: C
authors.lastname: Guan
authors.affiliation: Jinan Baofa Cancer Hospital, Jinan.
authors.forename: Yebing
authors.initials: Y
authors.lastname: Che
authors.affiliation: TaiMei Baofa Cancer Hospital, Dongping.
authors.forename: Yingli
authors.initials: Y
authors.lastname: Wu
authors.affiliation: TaiMei Baofa Cancer Hospital, Dongping.
authors.forename: Zhenlu
authors.initials: Z
authors.lastname: Ma
authors.affiliation: Jinan Baofa Cancer Hospital, Jinan.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Fu
authors.affiliation: TaiMei Baofa Cancer Hospital, Dongping.
authors.forename: Jian
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Pathology, University of California, San Diego, CA, USA.
authors.forename: Huan-You
authors.initials: HY
authors.lastname: Wang
keywords: hapten-enhanced immunotherapy; intratumoral chemoimmunotherapy; lung cancer; ultra-minimum incision therapy